Skip to content

US · BFRI · MEDICAL - PHARMACEUTICALS

Biofrontera Inc. (BFRI) intrinsic value and stock valuation

$0.53as of 2026-11-21 · Mkt cap 15.88M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Biofrontera Inc. DCF and intrinsic value

InvestorsCraft values BFRI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BFRI’s statements →

Biofrontera Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Woburn, MA 01801 biofrontera-us.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$41.7M+17.2% 5y CAGRd
20192025
Net income
-$-10.54M
20192025
Free cash flow
-$-13.36M
20192025
Total equity
$10.5M+12.4% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$41.7M$37.3M$34.1M$28.7M$24.1M
Operating income-$-9.15M-$-17.21M-$-22.68M-$-18.58M-$-25.2M
Net income-$-10.54M-$-17.76M-$-20.13M-$-640K-$-37.71M
EPSd-$-904.72K-$-3.22M-$-12.99M-$-603.77K-$-43.85M
Operating cash flow-$-13.36M-$-10.27M-$-24.89M-$-16.2M-$-26.71M
Capital expenditure-$0.00-$-60K-$-10K-$-40K-$-10K
Free cash flow-$-13.36M-$-10.33M-$-24.9M-$-16.24M-$-26.73M
Total assets$28.6M$22.1M$27.9M$50.9M$53.2M
Total debt$6.16M$4.92M$5.4M$1.35M$0.00
Net debt-$-230K-$-980K$4.06M-$-15.86M-$-24.55M
Total equity$10.5M$4.43M$4.79M$23.9M$11.3M
Cash and short-term investments$6.39M$5.91M$1.42M$27.8M$24.6M
Income statement
20252024202320222021
Revenue$41.7M$37.3M$34.1M$28.7M$24.1M
Cost of revenue$8.9M$18.6M$17.4M$15.2M$12.7M
Gross profit$32.8M$18.7M$16.6M$13.5M$11.4M
Research and development expenses$3.72M$2.09M$80K$0.00$0.00
Selling, general and administrative expenses$38.1M$33.8M$39.1M$35.9M$37.2M
Other expenses$100K$0.00$100K-$-3.8M-$-650K
Operating expenses$42M$35.9M$39.3M$32.1M$36.6M
Cost and expenses$50.9M$54.5M$56.8M$47.3M$49.3M
Interest income$0.00$30K$130K$170K$20K
Interest expense$450K$2.11M$600K$370K$360K
Depreciation and amortization$870K$1.15M$1.06M$1.17M$540K
Ebitda-$-9.19M-$-14.44M-$-18.45M$930K-$-36.76M
Operating income-$-9.15M-$-17.21M-$-22.68M-$-18.58M-$-25.2M
Total other income/expenses, net-$-1.36M-$-530K$2.56M$18M-$-12.46M
Income before tax-$-10.51M-$-17.74M-$-20.12M-$-610K-$-37.66M
Income tax expense$30K$20K$10K$30K$60K
Net income-$-10.54M-$-17.76M-$-20.13M-$-640K-$-37.71M
Weighted average shares outstanding$10.2M$5.52M$1.55M$1.06M$860K
Weighted average diluted shares outstanding$11.7M$5.52M$1.55M$1.06M$860K
Balance sheet
20252024202320222021
Cash and short-term investments$6.39M$5.91M$1.42M$27.8M$24.6M
Net receivables$7.29M$5.32M$5.16M$7.41M$3.78M
Inventory$1.43M$6.65M$10.9M$7.17M$4.46M
Total current assets$18.1M$20.7M$23.1M$43.1M$46.4M
Property, plant and equipment, net$3.74M$980K$1.75M$1.58M$270K
Goodwill and intangible assets$2.65M$40K$2.63M$3.03M$3.45M
Long-term investments$200K$0.00$0.00$0.00$2.81M
Total non-current assets$10.5M$1.4M$4.86M$7.74M$6.8M
Total assets$28.6M$22.1M$27.9M$50.9M$53.2M
Accounts payable$1.85M$1.86M$8.91M$1.28M$660K
Short-term debt$330K$550K$4.59M$500K$0.00
Deferred revenue$0.00$0.00$0.00$6.94M$3.24M
Total current liabilities$11.9M$12M$18.1M$20.9M$13.8M
Long-term debt$5.83M$4.37M$800K$850K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$2.4M$9.54M
Total non-current liabilities$6.19M$5.65M$5.05M$6.11M$28.1M
Capital lease obligations$330K$820K$1.5M$1.35M$0.00
Total liabilities$18.1M$17.7M$23.1M$27M$41.9M
Common stock$10K$10K$0.00$0.00$20K
Retained earnings-$-127.94M-$-117.41M-$-99.65M-$-79.52M-$-78.88M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$10.5M$4.43M$4.79M$23.9M$11.3M
Total investments$210K$10K$80K$10.6M$2.81M
Total debt$6.16M$4.92M$5.4M$1.35M$0.00
Net debt-$-230K-$-980K$4.06M-$-15.86M-$-24.55M
Cash flow statement
20252024202320222021
Net income-$-10.54M-$-17.76M-$-20.13M-$-640K-$-37.71M
Depreciation and amortization$140K$1.15M$1.06M$1.17M$540K
Stock-based compensation$950K$1.02M$1.04M$1.85M$130K
Change in working capital-$-3.48M$6.21M-$-4.39M$2.79M-$-1.5M
Accounts receivable-$-1.91M-$-310K$4.93M$4.92M-$-12M
Inventory$1.45M$4.23M-$-3.75M-$-2.81M$2.59M
Accounts payable-$-540K-$-1.81M$6.42M$0.00-$-770K
Net cash provided by operating activities-$-13.36M-$-10.27M-$-24.89M-$-16.2M-$-26.71M
Investments in property, plant and equipment-$0.00-$-10K-$-10K-$-40K-$-10K
Acquisitions, net$3M$0.00$0.00$0.00$0.00
Net cash used for investing activities$3M-$0.00$620K-$-5.16M-$-10K
Common stock issued$10.9M$0.00$4.51M$9.39M$29.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.9M$14.8M$8.41M$14M$43.2M
Net change in cash$490K$4.56M-$-15.87M-$-7.33M$16.5M
Cash at end of period$6.59M$6.11M$1.54M$17.4M$24.7M
Operating cash flow-$-13.36M-$-10.27M-$-24.89M-$-16.2M-$-26.71M
Capital expenditure-$0.00-$-60K-$-10K-$-40K-$-10K
Free cash flow-$-13.36M-$-10.33M-$-24.9M-$-16.24M-$-26.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Biofrontera Inc.

        Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

        CEO
        Hermann Lübbert
        Employees
        92
        Beta
        0.82

        Explore

        Frequently asked questions

        What is the intrinsic value of Biofrontera Inc. (BFRI)?

        InvestorsCraft does not currently publish an intrinsic value for BFRI. How the IC value is calculated.

        Is BFRI undervalued?

        InvestorsCraft does not publish an undervaluation signal for BFRI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.